End-of-day quote
Korea S.E.
18:00:00 2024-05-12 EDT
|
5-day change
|
1st Jan Change
|
1,019
KRW
|
-1.45%
|
|
-1.64%
|
-9.82%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
91,801
|
76,579
|
59,310
|
131,317
|
48,354
|
38,524
|
Enterprise Value (EV)
1 |
69,111
|
51,620
|
60,810
|
148,621
|
45,446
|
67,242
|
P/E ratio
|
-12.2
x
|
-195
x
|
-1.92
x
|
-3.67
x
|
-2.62
x
|
-2.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.98
x
|
2.04
x
|
4.55
x
|
5.1
x
|
0.62
x
|
0.4
x
|
EV / Revenue
|
4.5
x
|
1.38
x
|
4.66
x
|
5.77
x
|
0.58
x
|
0.69
x
|
EV / EBITDA
|
-382
x
|
-21.4
x
|
-172
x
|
-31.7
x
|
-19.6
x
|
-52.5
x
|
EV / FCF
|
22.3
x
|
-2.28
x
|
3.59
x
|
-3.37
x
|
-5.85
x
|
-10.1
x
|
FCF Yield
|
4.49%
|
-43.8%
|
27.9%
|
-29.7%
|
-17.1%
|
-9.92%
|
Price to Book
|
3.16
x
|
1.71
x
|
1.57
x
|
2.84
x
|
1.71
x
|
2.41
x
|
Nbr of stocks (in thousands)
|
10,955
|
12,936
|
16,475
|
32,344
|
32,344
|
34,092
|
Reference price
2 |
8,380
|
5,920
|
3,600
|
4,060
|
1,495
|
1,130
|
Announcement Date
|
3/20/19
|
3/18/20
|
3/23/21
|
3/25/22
|
3/23/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
15,350
|
37,484
|
13,049
|
25,764
|
78,061
|
96,991
|
EBITDA
1 |
-180.7
|
-2,416
|
-353.6
|
-4,687
|
-2,316
|
-1,281
|
EBIT
1 |
-751.2
|
-3,687
|
-834.6
|
-6,573
|
-8,803
|
-7,460
|
Operating Margin
|
-4.89%
|
-9.84%
|
-6.4%
|
-25.51%
|
-11.28%
|
-7.69%
|
Earnings before Tax (EBT)
1 |
-7,181
|
-4,598
|
-26,523
|
-31,836
|
-24,604
|
-20,047
|
Net income
1 |
-7,181
|
-367
|
-26,667
|
-29,489
|
-18,447
|
-13,813
|
Net margin
|
-46.78%
|
-0.98%
|
-204.35%
|
-114.46%
|
-23.63%
|
-14.24%
|
EPS
2 |
-684.1
|
-30.41
|
-1,875
|
-1,107
|
-570.4
|
-414.8
|
Free Cash Flow
1 |
3,100
|
-22,621
|
16,956
|
-44,105
|
-7,764
|
-6,669
|
FCF margin
|
20.2%
|
-60.35%
|
129.94%
|
-171.19%
|
-9.95%
|
-6.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/20/19
|
3/18/20
|
3/23/21
|
3/25/22
|
3/23/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
1,500
|
17,304
|
-
|
28,718
|
Net Cash position
1 |
22,690
|
24,960
|
-
|
-
|
2,908
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-4.243
x
|
-3.692
x
|
-
|
-22.42
x
|
Free Cash Flow
1 |
3,100
|
-22,621
|
16,956
|
-44,105
|
-7,764
|
-6,669
|
ROE (net income / shareholders' equity)
|
-28.7%
|
-5.98%
|
-38.6%
|
-41.3%
|
-23.2%
|
-24.2%
|
ROA (Net income/ Total Assets)
|
-1.26%
|
-2.41%
|
-0.51%
|
-3.38%
|
-3.14%
|
-2.53%
|
Assets
1 |
569,078
|
15,239
|
5,255,597
|
873,548
|
587,217
|
545,614
|
Book Value Per Share
2 |
2,653
|
3,458
|
2,288
|
1,430
|
873.0
|
469.0
|
Cash Flow per Share
2 |
3,056
|
4,104
|
487.0
|
1,044
|
1,489
|
1,176
|
Capex
1 |
526
|
1,491
|
1,707
|
22,180
|
5,635
|
17,658
|
Capex / Sales
|
3.42%
|
3.98%
|
13.08%
|
86.09%
|
7.22%
|
18.21%
|
Announcement Date
|
3/20/19
|
3/18/20
|
3/23/21
|
3/25/22
|
3/23/23
|
3/27/24
|
|
1st Jan change
|
Capi.
|
---|
| -9.82% | 25.56M | | +22.23% | 43.81B | | +25.56% | 23.01B | | +18.81% | 15.27B | | +9.95% | 13.68B | | +42.95% | 11.96B | | -7.49% | 6.98B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.26% | 5.59B |
Generic Pharmaceuticals
|